29662238 32088420 32169784 32352776 32071740 30128071 33272706 33479648 34763600 30404440 32277377 33904307 28904064 32797120 33138369 32916035 33644590 29557271 30640465 - Search Results

Year	Number of Results
2017	1
2018	4
2019	2
2020	10
2021	4
2022	1
2023	0

1

Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S. Katzenellenbogen JA, et al. Nat Rev Cancer. 2018 Jun;18(6):377-388. doi: 10.1038/s41568-018-0001-z. Nat Rev Cancer. 2018. PMID: 29662238 Free PMC article. Review.

2

A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.

Lu X, Huang A, Xiao M, Sun L, Mao J, Luo G, Xiang H. Lu X, et al. Bioorg Chem. 2020 Apr;97:103666. doi: 10.1016/j.bioorg.2020.103666. Epub 2020 Feb 13. Bioorg Chem. 2020. PMID: 32088420

3

Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.

Knox A, Kalchschmid C, Schuster D, Gaggia F, Manzl C, Baecker D, Gust R. Knox A, et al. Eur J Med Chem. 2020 Apr 15;192:112191. doi: 10.1016/j.ejmech.2020.112191. Epub 2020 Feb 28. Eur J Med Chem. 2020. PMID: 32169784

4

Monomeric Targeted Protein Degraders.

Hanan EJ, Liang J, Wang X, Blake RA, Blaquiere N, Staben ST. Hanan EJ, et al. J Med Chem. 2020 Oct 22;63(20):11330-11361. doi: 10.1021/acs.jmedchem.0c00093. Epub 2020 Jun 15. J Med Chem. 2020. PMID: 32352776 Review.

5

Synthesis and crystal structure of 3-(adamantan-1-yl)-4-(2-bromo-4-fluoro-phen-yl)-1H-1,2,4-triazole-5(4H)-thione.

Abdelrazeq AS, Ghabbour HA, El-Emam AA, Osman DA, Garcia-Granda S. Abdelrazeq AS, et al. Acta Crystallogr E Crystallogr Commun. 2020 Jan 10;76(Pt 2):162-166. doi: 10.1107/S2056989020000092. eCollection 2020 Feb 1. Acta Crystallogr E Crystallogr Commun. 2020. PMID: 32071740 Free PMC article.

6

New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.

Wang L, Guillen VS, Sharma N, Flessa K, Min J, Carlson KE, Toy W, Braqi S, Katzenellenbogen BS, Katzenellenbogen JA, Chandarlapaty S, Sharma A. Wang L, et al. ACS Med Chem Lett. 2018 Jul 5;9(8):803-808. doi: 10.1021/acsmedchemlett.8b00106. eCollection 2018 Aug 9. ACS Med Chem Lett. 2018. PMID: 30128071 Free PMC article.

7

Design, synthesis, and biological evaluation of new raloxifene analogues of improved antagonist activity and endometrial safety.

Lambrinidis G, Gouedard C, Stasinopoulou S, Angelopoulou A, Ganou V, Meligova AK, Mitsiou DJ, Marakos P, Pouli N, Mikros E, Alexis MN. Lambrinidis G, et al. Bioorg Chem. 2021 Jan;106:104482. doi: 10.1016/j.bioorg.2020.104482. Epub 2020 Nov 17. Bioorg Chem. 2021. PMID: 33272706

8

Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.

Shagufta, Ahmad I, Mathew S, Rahman S. Shagufta, et al. RSC Med Chem. 2020 Mar 6;11(4):438-454. doi: 10.1039/c9md00570f. eCollection 2020 Apr 1. RSC Med Chem. 2020. PMID: 33479648 Free PMC article. Review.

9

Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).

Scott JS, Barlaam B. Scott JS, et al. Expert Opin Ther Pat. 2022 Feb;32(2):131-151. doi: 10.1080/13543776.2022.2006185. Epub 2021 Dec 19. Expert Opin Ther Pat. 2022. PMID: 34763600 Review.

10

Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.

Sharma A, Toy W, Guillen VS, Sharma N, Min J, Carlson KE, Mayne CG, Lin S, Sabio M, Greene G, Katzenellenbogen BS, Chandarlapaty S, Katzenellenbogen JA. Sharma A, et al. ACS Chem Biol. 2018 Dec 21;13(12):3374-3384. doi: 10.1021/acschembio.8b00877. Epub 2018 Nov 26. ACS Chem Biol. 2018. PMID: 30404440 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results